Cardiovascular Drugs and Therapy

, Volume 28, Issue 1, pp 53–59 | Cite as

Eicosapentaenoic Acid Combined with Optimal Statin Therapy Improves Endothelial Dysfunction in Patients with Coronary Artery Disease

  • Kentaro Toyama
  • Toshihiko Nishioka
  • Ami Isshiki
  • Toshiyuki Ando
  • Yoshiro Inoue
  • Masato Kirimura
  • Tetsuo Kamiyama
  • Osamu Sasaki
  • Hiroyuki Ito
  • Yoshiaki Maruyama
  • Nobuo Yoshimoto



Eicosapentaenoic acid (EPA) has been reported to augment endothelial function and improve clinical outcomes in patients with coronary artery disease (CAD). The purpose of this study was to determine whether EPA could improve residual endothelial dysfunction despite adequate lipid-lowering with statin in CAD patients.


Eighty patients with established CAD, who had been on statin treatment and had serum low-density lipoprotein cholesterol (LDL-C) levels <100 mg/dl, were randomly assigned to receive either 1,800 mg of EPA daily plus statin (EPA group, n = 40) or statin alone (Control group, n = 40). Lipid profiles and flow-mediated dilation (FMD) were assessed just before and after more than 3 months of treatment in both groups. Only patients who had impaired FMD (<6 %) before randomization were enrolled.


After treatment for 5.2 ± 1.7 months, the EPA group showed a significant increase in the serum concentration of EPA and EPA to arachidonic acid (AA) (EPA/AA) ratio (62.5 ± 38.1 to 159.8 ± 53.8 μg/ml, 0.45 ± 0.34 to 1.20 ± 0.55, p < 0.01 for both). In the EPA group, serum triglycerides significantly decreased (150.7 ± 92.9 to 119.3 ± 60.7 mg/dl, p = 0.02), whereas no significant change was seen in the Control group. FMD, the primary study endpoint, showed a significant improvement in the EPA group (2.6 ± 1.6 % to 3.2 ± 1.6 %, p = 0.02), whereas no significant change was observed in the Control group (2.7 ± 1.6 % to 2.4 ± 1.7 %, p = 0.29).


EPA improved endothelial function and impaired FMD in patients with established CAD who were on optimal statin therapy.


Endothelial function Eicosapentaenoic acid Flow-mediated dilation Coronary artery disease Statin 


Conflict of Interest

There is no conflict of interest for this work.


  1. 1.
    Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52:1769–81.PubMedCrossRefGoogle Scholar
  2. 2.
    Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78.PubMedCrossRefGoogle Scholar
  4. 4.
    ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74.CrossRefGoogle Scholar
  5. 5.
    The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67.CrossRefGoogle Scholar
  6. 6.
    Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;2:757–61.PubMedCrossRefGoogle Scholar
  7. 7.
    GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354:447–55.CrossRefGoogle Scholar
  8. 8.
    Daviglus ML, Stamler J, Orencia AJ, et al. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med. 1997;336:1046–53.PubMedCrossRefGoogle Scholar
  9. 9.
    Hu FB, Bronner L, Willett WC, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA. 2002;287:1815–21.PubMedCrossRefGoogle Scholar
  10. 10.
    Iso H, Kobayashi M, Ishihara J, et al. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation. 2006;113:195–202.PubMedCrossRefGoogle Scholar
  11. 11.
    Ueeda M, Doumei T, Takaya Y, et al. Association of serum levels of arachidonic acid and eicosapentaenoic acid with prevalence of major adverse cardiac events after acute myocardial infarction. Heart Vessels. 2011;26:145–52.PubMedCrossRefGoogle Scholar
  12. 12.
    Matsuzaki M, Yokoyama M, Saito Y, et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J. 2009;73:1283–90.PubMedCrossRefGoogle Scholar
  13. 13.
    Nakamura N, Hamazaki T, Ohta M, et al. Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia. Int J Clin Lab Res. 1999;29:22–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Carrepeiro MM, Rogero MM, Bertolami MC, Botelho PB, Castro N, Castro IA. Effect of n-3 fatty acids and statins on oxidative stress in statin-treated hypercholestorelemic and normocholesterolemic women. Atherosclerosis. 2011;217:171–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Widlansky ME, Gokce N, Keaney Jr JF, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42:1149–60.PubMedCrossRefGoogle Scholar
  16. 16.
    Gokce N, Keaney Jr JF, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation. 2002;105:1567–72.PubMedCrossRefGoogle Scholar
  17. 17.
    Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation. 2007;115:2390–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Smith Jr SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458–73.PubMedCrossRefGoogle Scholar
  19. 19.
    Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257–65.PubMedCrossRefGoogle Scholar
  20. 20.
    Tomiyama H, Matsumoto C, Yamada J, et al. The relationships of cardiovascular disease risk factors to flow-mediated dilatation in Japanese subjects free of cardiovascular disease. Hypertens Res. 2008;31:2019–25.PubMedCrossRefGoogle Scholar
  21. 21.
    Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Nodari S, Metra M, Milesi G, et al. The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. Cardiovasc Drugs Ther. 2009;23:5–15.PubMedCrossRefGoogle Scholar
  23. 23.
    Baumann KH, Hessel F, Larass I, et al. Dietary omega-3, omega-6, and omega-9 unsaturated fatty acids and growth factor and cytokine gene expression in unstimulated and stimulated monocytes. A randomized volunteer study. Arterioscler Thromb Vasc Biol. 1999;19:59–66.PubMedCrossRefGoogle Scholar
  24. 24.
    Engler MB. Vascular relaxation to omega-3 fatty acids: comparison to sodium nitroprusside, nitroglycerin, papaverine, and D600. Cardiovasc Drugs Ther. 1992;6:605–10.PubMedCrossRefGoogle Scholar
  25. 25.
    Fleischhauer FJ, Yan WD, Fischell TA. Fish oil improves endothelium-dependent coronary vasodilation in heart transplant recipients. J Am Coll Cardiol. 1993;21:982–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Goodfellow J, Bellamy MF, Ramsey MW, Jones CJ, Lewis MJ. Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol. 2000;35:265–70.PubMedCrossRefGoogle Scholar
  27. 27.
    Knapp HR. Dietary fatty acids in human thrombosis and hemostasis. Am J Clin Nutr. 1997;65:1687S–98S.PubMedGoogle Scholar
  28. 28.
    Jacobson TA. Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Am J Clin Nutr. 2008;87:1981S–90S.PubMedGoogle Scholar
  29. 29.
    Kawano H, Yano T, Mizuguchi K, Mochizuki H, Saito Y. Changes in aspects such as the collagenous fiber density and foam cell size of atherosclerotic lesions composed of foam cells, smooth muscle cells and fibrous components in rabbits caused by all-cis-5, 8, 11, 14, 17-icosapentaenoic acid. J Atheroscler Thromb. 2002;9:170–7.PubMedGoogle Scholar
  30. 30.
    Takase B, Uehata A, Akima T, et al. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol. 1998;82:1535–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Cohn JN, Quyyumi AA, Hollenberg NK, Jamerson KA. Surrogate markers for cardiovascular disease: functional markers. Circulation. 2004;109:IV31–46.PubMedCrossRefGoogle Scholar
  32. 32.
    Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol. 2002;40:505–10.PubMedCrossRefGoogle Scholar
  33. 33.
    Kubota Y, Miyamoto M, Takagi G, et al. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci. 2012;27:1364–70.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Westerink J, Deanfield JE, Imholz BP, et al. High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study. Atherosclerosis. 2013;227:118–24.PubMedCrossRefGoogle Scholar
  35. 35.
    Nakamura T, Hirano M, Kitta Y, et al. A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. J Cardiol. 2012;60:12–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Nishimura M, Nanbu A, Komori T, Ohtsuka K, Takahashi H, Yoshimura M. Eicosapentaenoic acid stimulates nitric oxide production and decreases cardiac noradrenaline in diabetic rats. Clin Exp Pharmacol Physiol. 2000;27:618–24.PubMedCrossRefGoogle Scholar
  37. 37.
    Omura M, Kobayashi S, Mizukami Y, et al. Eicosapentaenoic acid (EPA) induces Ca(2+)-independent activation and translocation of endothelial nitric oxide synthase and endothelium-dependent vasorelaxation. FEBS Lett. 2001;487:361–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Domei T, Yokoi H, Kuramitsu S, et al. Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention. Circ J. 2012;76:423–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Tapiero H, Ba GN, Couvreur P, Tew KD. Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomed Pharmacother. 2002;56:215–22.PubMedCrossRefGoogle Scholar
  40. 40.
    Chowienczyk PJ, Watts GF, Wierzbicki AS, Cockcroft JR, Brett SE, Ritter JM. Preserved endothelial function in patients with severe hypertriglyceridemia and low functional lipoprotein lipase activity. J Am Coll Cardiol. 1997;29:964–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Rizza S, Tesauro M, Cardillo C, et al. Fish oil supplementation improves endothelial function in normoglycemic offspring of patients with type 2 diabetes. Atherosclerosis. 2009;206:569–74.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Griffin MD, Sanders TA, Davies IG, et al. Effects of altering the ratio of dietary n-6 to n-3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45–70 y: the OPTILIP Study. Am J Clin Nutr. 2006;84:1290–8.PubMedGoogle Scholar
  43. 43.
    Nordoy A, Bonaa KH, Sandset PM, et al. Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia. Arterioscler Thromb Vasc Biol. 2000;20:259–65.PubMedCrossRefGoogle Scholar
  44. 44.
    Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.PubMedCrossRefGoogle Scholar
  45. 45.
    LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–35.PubMedCrossRefGoogle Scholar
  46. 46.
    Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–45.PubMedCrossRefGoogle Scholar
  47. 47.
    Meyer BJ. Are we consuming enough long chain omega-3 polyunsaturated fatty acids for optimal health? Prostaglandins Leukot Essent Fatty Acids. 2011;85:275–80.PubMedCrossRefGoogle Scholar
  48. 48.
    Sekikawa A, Kadowaki T, El-Saed A, et al. Differential association of docosahexaenoic and eicosapentaenoic acids with carotid intima-media thickness. Stroke. 2011;42:2538–43.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Kentaro Toyama
    • 1
  • Toshihiko Nishioka
    • 1
  • Ami Isshiki
    • 1
  • Toshiyuki Ando
    • 1
  • Yoshiro Inoue
    • 1
  • Masato Kirimura
    • 1
  • Tetsuo Kamiyama
    • 1
  • Osamu Sasaki
    • 1
  • Hiroyuki Ito
    • 1
  • Yoshiaki Maruyama
    • 1
  • Nobuo Yoshimoto
    • 1
  1. 1.Department of Cardiology, Saitama Medical CenterSaitama Medical UniversityKawagoeJapan

Personalised recommendations